Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 31;15(7):3519-3521.
doi: 10.21037/jtd-23-678. Epub 2023 Jun 26.

Operable non-small cell lung cancer: induction therapy, adjuvant therapy, or both?

Apostolos C Agrafiotis  1 , Paul E Van Schil  1
Affiliations
Editorial

Operable non-small cell lung cancer: induction therapy, adjuvant therapy, or both?

Apostolos C Agrafiotis et al. J Thorac Dis. .
No abstract available

Keywords: Non-small cell lung cancer (NSCLC); adjuvant therapy; epidermal growth factor receptor (EGFR); immune checkpoint inhibitors (ICI); neoadjuvant treatment; tyrosine kinase inhibitors (TKI).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-678/coif). PEVS has the following conflicts of interest to declare: (I) advisory board and/or honoraria for lectures from AstraZeneca, BMS, Roche, MSD and Janssen and (II) president-elect IASLC (International Association for the Study of Lung Cancer) and treasurer BACTS (Belgian Association for Cardiothoracic Surgery). ACA has no conflicts of interest to declare.

Comment on

References

    1. Shinohara S, Takahashi Y, Masago K, et al. The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review. J Thorac Dis 2023;15:747-58. 10.21037/jtd-22-957 - DOI - PMC - PubMed
    1. Provencio M, Serna-Blasco R, Nadal E, et al. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). J Clin Oncol 2022;40:2924-33. 10.1200/JCO.21.02660 - DOI - PMC - PubMed
    1. Provencio M, Serna R, Nadal E, et al. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study. J Thorac Oncol 2022. Available online: 10.1016/j.jtho.2022.07.01410.1016/j.jtho.2022.07.014 - DOI - DOI
    1. Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med 2022;386:1973-85. 10.1056/NEJMoa2202170 - DOI - PMC - PubMed
    1. Bristol Myers Squibb - Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial (bms.com) (accessed on 07/04/2023).